VGI Health Technology (XNEC:VTL) FCF Yield % : 0.00 (As of May. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, VGI Health Technology's Trailing 12-Month Free Cash Flow is A$0.00 Mil, and Market Cap is A$0.00 Mil. Therefore, VGI Health Technology's FCF Yield % for today is 0.00%.

The historical rank and industry rank for VGI Health Technology's FCF Yield % or its related term are showing as below:

XNEC:VTL's FCF Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: -14.39
* Ranked among companies with meaningful FCF Yield % only.

VGI Health Technology's FCF Margin % for the quarter that ended in . 20 was 0.00%.

VGI Health Technology FCF Yield % Historical Data

The historical data trend for VGI Health Technology's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology FCF Yield % Chart

VGI Health Technology Annual Data

Trend

FCF Yield %

VGI Health Technology Semi-Annual Data

FCF Yield %

Competitive Comparison of VGI Health Technology's FCF Yield %

For the Biotechnology subindustry, VGI Health Technology's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's FCF Yield % distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's FCF Yield % falls into.

VGI Health Technology FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

VGI Health Technology's FCF Yield % for the fiscal year that ended in . 20 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=		/
	=	N/A%

VGI Health Technology's annualized FCF Yield % for the quarter that ended in . 20 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=		*	1	/
	=	N/A%

VGI Health Technology FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

VGI Health Technology FCF Yield % Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines